[Form 4/A] Amneal Pharmaceuticals, Inc. Amended Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Amneal Pharmaceuticals President & Co-CEO Chirag K. Patel received a grant of 544,663 performance-based restricted stock units tied to Class A common stock. These units do not involve a cash purchase and represent a compensation award that can convert into shares in the future.

The award is based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The number of shares ultimately earned can range from 0% to 200% of the 544,663 target, with the table reflecting the maximum shares potentially issuable. Any units that are earned will vest in full on February 28, 2029, at the end of the performance period.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patel Chirag K.

Role President & Co-CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Restricted Stock Units	544,663	$0.00	--

Holdings After Transaction: Performance-Based Restricted Stock Units — 544,663 shares (Direct)

Footnotes (1)

Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chirag K.

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

NEW JERSEY

08807

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & Co-CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Performance-Based Restricted Stock Units	⁽¹⁾	03/02/2026		A		544,663		⁽²⁾	⁽²⁾	Class A Common Stock	544,663	$0	544,663	D

Explanation of Responses:

1. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

This amended Form 4 amends and restates the Form 4 filed on March 3, 2026 (the "Original Form 4") and is being filed to correct the number of restricted stock units and performance-based restricted stock units granted to the reporting person. The Original Form 4 inadvertently reported a grant of restricted stock units; however, 100% of the grant was of performance-based restricted stock units.

	/s/ Denis Butkovic, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Amneal (AMRX) President & Co-CEO Chirag K. Patel report on this Form 4/A?

Chirag K. Patel reported receiving 544,663 performance-based restricted stock units as an equity compensation award. These units may convert into Amneal Class A common shares if long-term stock price targets are met over a three-year performance period ending February 28, 2029.

How many Amneal (AMRX) performance-based units were granted to Chirag K. Patel?

The award covers 544,663 performance-based restricted stock units tied to Amneal’s Class A common stock. This figure represents the target grant, and the table in the filing shows the maximum number of shares that could be issued if the highest performance conditions are fully achieved.

What determines how many Amneal (AMRX) shares Chirag K. Patel ultimately receives from this grant?

The number of shares earned depends on Amneal’s Class A common stock reaching specific average closing price targets over the three-year performance period. The payout can range from 0% to 200% of the 544,663 target units, with actual shares issued only if performance conditions are met.

When do Chirag K. Patel’s Amneal (AMRX) performance-based restricted stock units vest?

Any performance-based restricted stock units that are earned will vest in full on February 28, 2029. This date marks the end of the three-year performance period used to measure Amneal’s stock price targets, after which eligible units convert into Class A common shares.

Is Chirag K. Patel buying or selling Amneal (AMRX) shares in this Form 4/A?

The filing shows an acquisition of performance-based restricted stock units as a compensation grant, not an open-market stock purchase or sale. No cash transaction price is reported, and the units will only convert into Amneal Class A shares if long-term performance criteria are satisfied.

What does the 0% to 200% range mean for Chirag K. Patel’s Amneal (AMRX) award?

The 0% to 200% range means Patel could receive no shares if performance goals are missed, or up to double the 544,663 target units if top performance levels are reached. The filing reports the maximum possible shares that could become issuable under this structure.